| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| ACP5 | BGLAP | ENSP00000218758 | ENSP00000357255 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | 0.824 |
| ACP5 | CTSK | ENSP00000218758 | ENSP00000271651 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | 0.872 |
| ACP5 | ENPP1 | ENSP00000218758 | ENSP00000354238 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | ectonucleotide pyrophosphatase/phosphodiesterase 1; By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing further growth of these crystals. In vitro, has a broad specificity, hydrolyzing other nucleoside 5’ triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3’,5’-cAMP to AMP. May also be involved in the regu [...] | 0.916 |
| ACP5 | ENPP3 | ENSP00000218758 | ENSP00000350265 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | ectonucleotide pyrophosphatase/phosphodiesterase 3; Cleaves a variety of phosphodiester and phosphosulfate bonds including deoxynucleotides, nucleotide sugars, and NAD (By similarity) | 0.900 |
| ACP5 | FLAD1 | ENSP00000218758 | ENSP00000292180 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | FAD1 flavin adenine dinucleotide synthetase homolog (S. cerevisiae); Catalyzes the adenylation of flavin mononucleotide (FMN) to form flavin adenine dinucleotide (FAD) coenzyme | 0.900 |
| ACP5 | IL4 | ENSP00000218758 | ENSP00000231449 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | interleukin 4; Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes | 0.874 |
| ACP5 | RFK | ENSP00000218758 | ENSP00000365926 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | riboflavin kinase; Catalyzes the phosphorylation of riboflavin (vitamin B2) to form flavin-mononucleotide (FMN), hence rate-limiting enzyme in the synthesis of FAD. Essential for TNF-induced reactive oxygen species (ROS) production. Through its interaction with both TNFRSF1A and CYBA, physically and functionally couples TNFRSF1A to NADPH oxidase. TNF-activation of RFK may enhance the incorporation of FAD in NADPH oxidase, a critical step for the assembly and activation of NADPH oxidase | 0.900 |
| ACP5 | SPP1 | ENSP00000218758 | ENSP00000378517 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | secreted phosphoprotein 1 | 0.960 |
| ACP5 | TNFRSF11B | ENSP00000218758 | ENSP00000297350 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | tumor necrosis factor receptor superfamily, member 11b; Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis | 0.871 |
| ACP5 | TNFSF11 | ENSP00000218758 | ENSP00000239849 | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | tumor necrosis factor (ligand) superfamily, member 11; Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy | 0.820 |
| BGLAP | ACP5 | ENSP00000357255 | ENSP00000218758 | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | 0.824 |
| BGLAP | CTSK | ENSP00000357255 | ENSP00000271651 | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | 0.533 |
| BGLAP | SPP1 | ENSP00000357255 | ENSP00000378517 | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | secreted phosphoprotein 1 | 0.909 |
| BGLAP | TNFRSF11B | ENSP00000357255 | ENSP00000297350 | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | tumor necrosis factor receptor superfamily, member 11b; Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis | 0.818 |
| BGLAP | TNFSF11 | ENSP00000357255 | ENSP00000239849 | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | tumor necrosis factor (ligand) superfamily, member 11; Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy | 0.809 |
| CTSK | ACP5 | ENSP00000271651 | ENSP00000218758 | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | 0.872 |
| CTSK | BGLAP | ENSP00000271651 | ENSP00000357255 | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | bone gamma-carboxyglutamate (gla) protein; Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium | 0.533 |
| CTSK | TNFRSF11B | ENSP00000271651 | ENSP00000297350 | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | tumor necrosis factor receptor superfamily, member 11b; Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis | 0.725 |
| CTSK | TNFSF11 | ENSP00000271651 | ENSP00000239849 | cathepsin K; Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation | tumor necrosis factor (ligand) superfamily, member 11; Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy | 0.949 |
| ENPP1 | ACP5 | ENSP00000354238 | ENSP00000218758 | ectonucleotide pyrophosphatase/phosphodiesterase 1; By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing further growth of these crystals. In vitro, has a broad specificity, hydrolyzing other nucleoside 5’ triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3’,5’-cAMP to AMP. May also be involved in the regu [...] | acid phosphatase 5, tartrate resistant; Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias | 0.916 |
Share
